NCT02831842View on ClinicalTrials.gov

A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status

CompletedOBSERVATIONAL

Enrollment

4,278

Participants

Timeline

Start Date

June 9, 2016

Primary Completion Date

June 9, 2016

Study Completion Date

November 30, 2017

Conditions

Colorectal Cancer

Interventions

DRUG

Anti-EGFR-Containing Regimen

Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.

DRUG

Bevacizumab-containing regimen

Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.

DRUG

Chemotherapy

Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02831842 - A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status | Biotech Hunter | Biotech Hunter